Parallax Volatility Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Parallax Volatility Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-67,500	Closed	-$8.37M	–	3449
2018 Q4	$8.37M	Hold	67,500	–	–	0.01%	568
2018 Q3	$11.3M	Buy	+67,500	New	+$11.6M	0.01%	431
2018 Q1	–	Sell	-34,000	Closed	-$4.58M	–	3299
2017 Q4	$4.58M	Hold	34,000	–	–	0.01%	635
2017 Q3	$4.97M	Buy	+34,000	New	+$5.14M	0.01%	570
2017 Q2	–	Sell	-25,000	Closed	-$3.63M	–	3149
2017 Q1	$3.63M	Buy	25,000 +12,500	+100%	+$1.63M	0.01%	664
2016 Q4	$1.36M	Hold	12,500	–	–	﹤0.01%	1111
2016 Q3	$1.52M	Buy	+12,500	New	+$1.68M	﹤0.01%	1088
2016 Q2	–	Sell	-27,200	Closed	-$3.55M	–	3080
2016 Q1	$3.55M	Buy	27,200 +23,200	+580%	+$2.89M	0.01%	696
2015 Q4	$562K	Buy	+4,000	New	+$554K	﹤0.01%	1497

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Parallax Volatility Advisers's JAZZ Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 14 shares — an estimated $2K sold.

Parallax Volatility Advisers first reported a position in JAZZ in Q4 2015 and held it in 10 quarters. The position peaked at $6.76M in Q4 2018. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

Parallax Volatility Advisers reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Parallax Volatility Advisers sold 14 Jazz Pharmaceuticals shares in Q3 2019, an estimated $2K.
Parallax Volatility Advisers first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 10 quarters.
Parallax Volatility Advisers's Jazz Pharmaceuticals position peaked at $6.76M in Q4 2018.
406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.